Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTCYQH4F)

DOT Name Trefoil factor 1 (TFF1)
Synonyms Breast cancer estrogen-inducible protein; PNR-2; Polypeptide P1.A; hP1.A; Protein pS2
Gene Name TFF1
UniProt ID
TFF1_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
1HI7; 1PS2; 6V1D
Pfam ID
PF00088
Sequence
MATMENKVICALVLVSMLALGTLAEAQTETCTVAPRERQNCGFPGVTPSQCANKGCCFDD
TVRGVPWCFYPNTIDVPPEEECEF
Function Stabilizer of the mucous gel overlying the gastrointestinal mucosa that provides a physical barrier against various noxious agents. May inhibit the growth of calcium oxalate crystals in urine.
Tissue Specificity
Found in stomach, with highest levels in the upper gastric mucosal cells (at protein level). Detected in goblet cells of the small and large intestine and rectum, small submucosal glands in the esophagus, mucous acini of the sublingual gland, submucosal glands of the trachea, and epithelial cells lining the exocrine pancreatic ducts but not in the remainder of the pancreas (at protein level). Scattered expression is detected in the epithelial cells of the gallbladder and submucosal glands of the vagina, and weak expression is observed in the bronchial goblet cells of the pseudostratified epithelia in the respiratory system (at protein level). Detected in urine (at protein level). Strongly expressed in breast cancer but at low levels in normal mammary tissue. It is regulated by estrogen in MCF-7 cells. Strong expression found in normal gastric mucosa and in the regenerative tissues surrounding ulcerous lesions of gastrointestinal tract, but lower expression found in gastric cancer (at protein level).
KEGG Pathway
Estrogen sig.ling pathway (hsa04915 )
Reactome Pathway
Estrogen-dependent gene expression (R-HSA-9018519 )

Molecular Interaction Atlas (MIA) of This DOT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
This DOT Affected the Drug Response of 2 Drug(s)
Drug Name Drug ID Highest Status Interaction REF
Paclitaxel DMLB81S Approved Trefoil factor 1 (TFF1) increases the response to substance of Paclitaxel. [54]
Capecitabine DMTS85L Approved Trefoil factor 1 (TFF1) increases the response to substance of Capecitabine. [55]
------------------------------------------------------------------------------------
69 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate affects the expression of Trefoil factor 1 (TFF1). [1]
Ciclosporin DMAZJFX Approved Ciclosporin increases the expression of Trefoil factor 1 (TFF1). [2]
Doxorubicin DMVP5YE Approved Doxorubicin decreases the expression of Trefoil factor 1 (TFF1). [3]
Cupric Sulfate DMP0NFQ Approved Cupric Sulfate increases the expression of Trefoil factor 1 (TFF1). [4]
Estradiol DMUNTE3 Approved Estradiol increases the expression of Trefoil factor 1 (TFF1). [5]
Arsenic DMTL2Y1 Approved Arsenic decreases the expression of Trefoil factor 1 (TFF1). [6]
Quercetin DM3NC4M Approved Quercetin increases the expression of Trefoil factor 1 (TFF1). [7]
Arsenic trioxide DM61TA4 Approved Arsenic trioxide increases the expression of Trefoil factor 1 (TFF1). [8]
Hydrogen peroxide DM1NG5W Approved Hydrogen peroxide affects the expression of Trefoil factor 1 (TFF1). [9]
Calcitriol DM8ZVJ7 Approved Calcitriol increases the expression of Trefoil factor 1 (TFF1). [10]
Testosterone DM7HUNW Approved Testosterone increases the expression of Trefoil factor 1 (TFF1). [11]
Triclosan DMZUR4N Approved Triclosan increases the expression of Trefoil factor 1 (TFF1). [12]
Progesterone DMUY35B Approved Progesterone decreases the expression of Trefoil factor 1 (TFF1). [13]
Menadione DMSJDTY Approved Menadione affects the expression of Trefoil factor 1 (TFF1). [9]
Fulvestrant DM0YZC6 Approved Fulvestrant decreases the expression of Trefoil factor 1 (TFF1). [14]
Dexamethasone DMMWZET Approved Dexamethasone increases the expression of Trefoil factor 1 (TFF1). [11]
Diethylstilbestrol DMN3UXQ Approved Diethylstilbestrol increases the expression of Trefoil factor 1 (TFF1). [15]
Rosiglitazone DMILWZR Approved Rosiglitazone increases the expression of Trefoil factor 1 (TFF1). [16]
Amphotericin B DMTAJQE Approved Amphotericin B increases the expression of Trefoil factor 1 (TFF1). [17]
Permethrin DMZ0Q1G Approved Permethrin increases the expression of Trefoil factor 1 (TFF1). [18]
Ethinyl estradiol DMODJ40 Approved Ethinyl estradiol increases the expression of Trefoil factor 1 (TFF1). [19]
Lindane DMB8CNL Approved Lindane increases the expression of Trefoil factor 1 (TFF1). [20]
Estrone DM5T6US Approved Estrone increases the expression of Trefoil factor 1 (TFF1). [21]
Estriol DMOEM2I Approved Estriol increases the expression of Trefoil factor 1 (TFF1). [21]
Exemestane DM9HPW3 Approved Exemestane increases the expression of Trefoil factor 1 (TFF1). [22]
Reserpine DM6VM38 Approved Reserpine increases the expression of Trefoil factor 1 (TFF1). [19]
Spironolactone DM2AQ5N Approved Spironolactone increases the expression of Trefoil factor 1 (TFF1). [19]
ARZOXIFENE DMOKCVI Approved ARZOXIFENE decreases the expression of Trefoil factor 1 (TFF1). [23]
Benzyl benzoate DMDPYI5 Approved Benzyl benzoate increases the expression of Trefoil factor 1 (TFF1). [24]
Methyltestosterone DMWLFGO Approved Methyltestosterone increases the expression of Trefoil factor 1 (TFF1). [19]
Nandrolone DMFWKG1 Approved Nandrolone increases the expression of Trefoil factor 1 (TFF1). [19]
Ospemifene DMC4GEI Approved Ospemifene decreases the expression of Trefoil factor 1 (TFF1). [25]
Dihydrotestosterone DM3S8XC Phase 4 Dihydrotestosterone increases the expression of Trefoil factor 1 (TFF1). [26]
SNDX-275 DMH7W9X Phase 3 SNDX-275 decreases the expression of Trefoil factor 1 (TFF1). [27]
Resveratrol DM3RWXL Phase 3 Resveratrol increases the expression of Trefoil factor 1 (TFF1). [28]
Coprexa DMA0WEK Phase 3 Coprexa decreases the expression of Trefoil factor 1 (TFF1). [29]
I3C DMIGFOR Phase 3 I3C decreases the expression of Trefoil factor 1 (TFF1). [30]
Guaiacol DMN4E7T Phase 3 Guaiacol increases the expression of Trefoil factor 1 (TFF1). [31]
ICARIIN DMOJQGT Phase 3 ICARIIN increases the expression of Trefoil factor 1 (TFF1). [32]
Genistein DM0JETC Phase 2/3 Genistein increases the expression of Trefoil factor 1 (TFF1). [33]
Belinostat DM6OC53 Phase 2 Belinostat decreases the expression of Trefoil factor 1 (TFF1). [27]
Afimoxifene DMFORDT Phase 2 Afimoxifene decreases the expression of Trefoil factor 1 (TFF1). [34]
phorbol 12-myristate 13-acetate DMJWD62 Phase 2 phorbol 12-myristate 13-acetate increases the expression of Trefoil factor 1 (TFF1). [35]
ACYLINE DM9GRTK Phase 2 ACYLINE increases the expression of Trefoil factor 1 (TFF1). [36]
(+)-JQ1 DM1CZSJ Phase 1 (+)-JQ1 decreases the expression of Trefoil factor 1 (TFF1). [38]
GSK525762 DMPAWBN Phase 1 GSK525762 decreases the expression of Trefoil factor 1 (TFF1). [38]
HEXESTROL DM9AGWQ Withdrawn from market HEXESTROL increases the expression of Trefoil factor 1 (TFF1). [19]
MX-4509 DMC4RK7 Discontinued in Phase 1 MX-4509 increases the expression of Trefoil factor 1 (TFF1). [19]
Bisphenol A DM2ZLD7 Investigative Bisphenol A increases the expression of Trefoil factor 1 (TFF1). [5]
Trichostatin A DM9C8NX Investigative Trichostatin A decreases the expression of Trefoil factor 1 (TFF1). [39]
Coumestrol DM40TBU Investigative Coumestrol increases the expression of Trefoil factor 1 (TFF1). [21]
methyl p-hydroxybenzoate DMO58UW Investigative methyl p-hydroxybenzoate increases the expression of Trefoil factor 1 (TFF1). [40]
Cycloheximide DMGDA3C Investigative Cycloheximide increases the expression of Trefoil factor 1 (TFF1). [41]
Dibutyl phthalate DMEDGKO Investigative Dibutyl phthalate increases the expression of Trefoil factor 1 (TFF1). [42]
Kaempferol DMHEMUB Investigative Kaempferol increases the expression of Trefoil factor 1 (TFF1). [7]
OXYBENZONE DMMZYX6 Investigative OXYBENZONE increases the expression of Trefoil factor 1 (TFF1). [43]
Daidzein DMRFTJX Investigative Daidzein increases the expression of Trefoil factor 1 (TFF1). [44]
27-hydroxycholesterol DM2L6OZ Investigative 27-hydroxycholesterol increases the expression of Trefoil factor 1 (TFF1). [45]
[3H]cAMP DMZRQU7 Investigative [3H]cAMP increases the expression of Trefoil factor 1 (TFF1). [46]
N-nonylphenol DMH3OUX Investigative N-nonylphenol increases the expression of Trefoil factor 1 (TFF1). [47]
Tetramethylbutylphenol DMW9CH2 Investigative Tetramethylbutylphenol increases the expression of Trefoil factor 1 (TFF1). [19]
MANGOSTIN DMYQGDV Investigative MANGOSTIN decreases the expression of Trefoil factor 1 (TFF1). [48]
ISORHAMNETIN DMQ4Z6E Investigative ISORHAMNETIN increases the expression of Trefoil factor 1 (TFF1). [7]
Ginsenoside Re DM46FVD Investigative Ginsenoside Re increases the expression of Trefoil factor 1 (TFF1). [49]
HPTE DMRPZD4 Investigative HPTE increases the expression of Trefoil factor 1 (TFF1). [50]
toxaphene DM4R657 Investigative toxaphene decreases the expression of Trefoil factor 1 (TFF1). [51]
M-Phenoxybenzoic Acid For Cis-Isomer DMJRK47 Investigative M-Phenoxybenzoic Acid For Cis-Isomer increases the expression of Trefoil factor 1 (TFF1). [52]
Equilin DM2Q19U Investigative Equilin increases the expression of Trefoil factor 1 (TFF1). [21]
TFMPP DMAC8TP Investigative TFMPP increases the expression of Trefoil factor 1 (TFF1). [53]
------------------------------------------------------------------------------------
⏷ Show the Full List of 69 Drug(s)
1 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene increases the methylation of Trefoil factor 1 (TFF1). [37]
------------------------------------------------------------------------------------

References

1 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
2 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
3 Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85. Mol Pharm. 2006 Mar-Apr;3(2):113-23.
4 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
5 Estrogenic effect of a series of bisphenol analogues on gene and protein expression in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 2002 Sep;82(1):45-53. doi: 10.1016/s0960-0760(02)00146-2.
6 Inorganic arsenic promotes luminal to basal transition and metastasis of breast cancer. FASEB J. 2020 Dec;34(12):16034-16048. doi: 10.1096/fj.202001192R. Epub 2020 Oct 13.
7 Estrogenic activities of Ginkgo biloba extracts. Life Sci. 2004 Jan 30;74(11):1325-35. doi: 10.1016/j.lfs.2003.06.045.
8 Arsenic induces functional re-expression of estrogen receptor by demethylation of DNA in estrogen receptor-negative human breast cancer. PLoS One. 2012;7(4):e35957. doi: 10.1371/journal.pone.0035957. Epub 2012 Apr 27.
9 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
10 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
11 Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model. Toxicol Sci. 2005 Feb;83(2):257-63.
12 The in vitro estrogenic activities of triclosan and triclocarban. J Appl Toxicol. 2014 Sep;34(9):1060-7. doi: 10.1002/jat.3012. Epub 2014 Apr 16.
13 Progesterone regulation of implantation-related genes: new insights into the role of oestrogen. Cell Mol Life Sci. 2007 Apr;64(7-8):1009-32.
14 Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Int J Cancer. 2004 Mar 20;109(2):167-73. doi: 10.1002/ijc.11720.
15 Assaying estrogenicity by quantitating the expression levels of endogenous estrogen-regulated genes. Environ Health Perspect. 2000 May;108(5):403-12.
16 Transactivation of ERalpha by Rosiglitazone induces proliferation in breast cancer cells. Breast Cancer Res Treat. 2008 Mar;108(1):23-33. doi: 10.1007/s10549-007-9575-y. Epub 2007 Apr 24.
17 Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
18 Estrogenicity of organophosphorus and pyrethroid pesticides. J Toxicol Environ Health A. 2002 Oct 11;65(19):1419-35. doi: 10.1080/00984100290071243.
19 Evaluation of an imaging-based in vitro screening platform for estrogenic activity with OECD reference chemicals. Toxicol In Vitro. 2022 Jun;81:105348. doi: 10.1016/j.tiv.2022.105348. Epub 2022 Mar 18.
20 Serum free BG-1 cell proliferation assay: a sensitive method for determining organochlorine pesticide estrogen receptor activation at the nanomolar range. Toxicol In Vitro. 2006 Apr;20(3):382-94. doi: 10.1016/j.tiv.2005.08.016. Epub 2005 Oct 19.
21 Tartrazine and sunset yellow are xenoestrogens in a new screening assay to identify modulators of human oestrogen receptor transcriptional activity. Toxicology. 2012 Aug 16;298(1-3):40-51. doi: 10.1016/j.tox.2012.04.014. Epub 2012 May 3.
22 Characterization of the weak estrogen receptor alpha agonistic activity of exemestane. Breast Cancer Res Treat. 2009 Aug;116(3):461-70. doi: 10.1007/s10549-008-0151-x. Epub 2008 Aug 3.
23 The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells. Mol Cell Endocrinol. 2004 Apr 30;219(1-2):27-36. doi: 10.1016/j.mce.2004.02.003.
24 Oestrogenic activity of benzyl salicylate, benzyl benzoate and butylphenylmethylpropional (Lilial) in MCF7 human breast cancer cells in vitro. J Appl Toxicol. 2009 Jul;29(5):422-34. doi: 10.1002/jat.1429.
25 Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo. Menopause. 2016 Jul;23(7):719-30. doi: 10.1097/GME.0000000000000624.
26 Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway. Chem Biol Interact. 2017 Sep 25;275:22-34. doi: 10.1016/j.cbi.2017.07.023. Epub 2017 Jul 27.
27 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
28 Structure-activity relationships of resveratrol and derivatives in breast cancer cells. Mol Nutr Food Res. 2009 Jul;53(7):845-58. doi: 10.1002/mnfr.200800331.
29 Copper deprivation enhances the chemosensitivity of pancreatic cancer to rapamycin by mTORC1/2 inhibition. Chem Biol Interact. 2023 Sep 1;382:110546. doi: 10.1016/j.cbi.2023.110546. Epub 2023 Jun 7.
30 Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells. J Nutr. 2000 Dec;130(12):2927-31. doi: 10.1093/jn/130.12.2927.
31 Oral administration of Brazilian propolis exerts estrogenic effect in ovariectomized rats. J Toxicol Sci. 2015 Apr;40(2):235-42. doi: 10.2131/jts.40.235.
32 Proliferation-stimulating effects of icaritin and desmethylicaritin in MCF-7 cells. Eur J Pharmacol. 2004 Nov 19;504(3):147-53. doi: 10.1016/j.ejphar.2004.10.002.
33 Oestrogenic potencies of Zeranol, oestradiol, diethylstilboestrol, Bisphenol-A and genistein: implications for exposure assessment of potential endocrine disrupters. Hum Reprod. 2001 May;16(5):1037-45.
34 Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
35 Phorbol ester-modulation of estrogenic genomic effects triggered by the environmental contaminant benzanthracene. Toxicol In Vitro. 2012 Sep;26(6):807-16.
36 Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007 May 15;67(10):5033-41.
37 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
38 An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul;24(7):809-19. doi: 10.1038/cr.2014.71. Epub 2014 May 30.
39 The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor expression. Mol Cell Biochem. 2012 Jul;366(1-2):111-22. doi: 10.1007/s11010-012-1288-9. Epub 2012 Apr 4.
40 Flow cytometric cell cycle analysis allows for rapid screening of estrogenicity in MCF-7 breast cancer cells. Toxicol In Vitro. 2006 Oct;20(7):1238-48. doi: 10.1016/j.tiv.2006.05.002. Epub 2006 May 16.
41 Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
42 Inhibitory effect of silver nanoparticles on proliferation of estrogen-dependent MCF-7/BUS human breast cancer cells induced by butyl paraben or di-n-butyl phthalate. Toxicol Appl Pharmacol. 2017 Dec 15;337:12-21. doi: 10.1016/j.taap.2017.10.014. Epub 2017 Oct 23.
43 Additive estrogenic effects of mixtures of frequently used UV filters on pS2-gene transcription in MCF-7 cells. Toxicol Appl Pharmacol. 2005 Oct 15;208(2):170-7. doi: 10.1016/j.taap.2005.02.006.
44 Isoflavone metabolites and their in vitro dual functions: they can act as an estrogenic agonist or antagonist depending on the estrogen concentration. J Steroid Biochem Mol Biol. 2006 Nov;101(4-5):246-53. doi: 10.1016/j.jsbmb.2006.06.020. Epub 2006 Sep 11.
45 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol. 2008 Jan;22(1):65-77. doi: 10.1210/me.2007-0383. Epub 2007 Sep 13.
46 CARM1 mediates the ligand-independent and tamoxifen-resistant activation of the estrogen receptor alpha by cAMP. Genes Dev. 2010 Apr 1;24(7):708-19. doi: 10.1101/gad.568410.
47 Estrogen-like properties of fluorotelomer alcohols as revealed by mcf-7 breast cancer cell proliferation. Environ Health Perspect. 2006 Jan;114(1):100-5. doi: 10.1289/ehp.8149.
48 -Mangostin-induced apoptosis is mediated by estrogen receptor in human breast cancer cells. Food Chem Toxicol. 2014 Apr;66:158-65. doi: 10.1016/j.fct.2014.01.040. Epub 2014 Jan 28.
49 Metabolism of ginsenoside Re by human intestinal microflora and its estrogenic effect. Biol Pharm Bull. 2005 Oct;28(10):1903-8. doi: 10.1248/bpb.28.1903.
50 Endocrine-Disrupting Chemicals (EDCs): In Vitro Mechanism of Estrogenic Activation and Differential Effects on ER Target Genes. Environ Health Perspect. 2013 Apr;121(4):459-66. doi: 10.1289/ehp.1205951. Epub 2013 Feb 5.
51 Effect of toxaphene on estrogen receptor functions in human breast cancer cells. Carcinogenesis. 1997 Aug;18(8):1651-4. doi: 10.1093/carcin/18.8.1651.
52 Estrogenic activities of two synthetic pyrethroids and their metabolites. J Environ Sci (China). 2010;22(2):290-6. doi: 10.1016/s1001-0742(09)60107-8.
53 Estrogenic effects and their action mechanism of the major active components of party pill drugs. Toxicol Lett. 2012 Nov 15;214(3):339-47. doi: 10.1016/j.toxlet.2012.09.014. Epub 2012 Sep 28.
54 cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat. 2006 Mar;96(1):17-39. doi: 10.1007/s10549-005-9026-6. Epub 2005 Dec 2.
55 Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. Cancer Sci. 2006 Jun;97(6):510-22. doi: 10.1111/j.1349-7006.2006.00204.x.